NRAS Mutation Detection Kit
- FOB Price:Get Latest Price >
- Min.Order:1 Box(es)
- Payment Terms:T/T , Others
- Favorite
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
8/10
Amoy Diagnostics Co.,Ltd.
Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS technologies, AmoyDx has a market-leading portfolio of molecular diagnostic kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA and ROS1 testing kits, which were firstly approved by CFDA and CE certified.
In European EMQN and Chinese PQCC quality control programs, AmoyDx is the NO.1 testing kit supplier for some years and always achieves the highest accuracy rate. Nowadays AmoyDx serves an extensive domestic and international oncology network reaching over 300 hospitals in China and 50 countries all over the world. Every year hundreds of thousands of cancer patients benefit from AmoyDx products.
AmoyDx is strategic diagnostics partner of AstraZeneca, Boehringer-Ingelheim, Pfizer, Merck and Illumina, providing diagnostic products and services for medicine development and clinical oncology practice. AmoyDx ROS1 kit was recently approved by Japanese authority PMDA as the sole companion diagnostic kit for Pfizer’s crizotinib, which became the 1st approved CDx kit in the world for lung cancer patients’ ROS1 testing.
Our mission is to provide customers with superior and innovative products and services to improve healthcare and patients’ lives. Our vision is to be one of the global leading and most reliable suppliers of high quality diagnostic products and services for personalized healthcare.
We endeavor to accomplish this mission and vision by:
1. Adhering to the strictest manufacturing standards to provide quality products at competitive prices.
2. Maintaining an unsurpassed level of customer service and satisfaction.
3. Pursuing scientific innovation as we provide customers with practical leading-edge technologies and value-added products.
4. Creating a world-class organization that contributes positively to the lives of our employees, our customers, the patients and the scientific community.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
8/10
NRAS Mutation Detection Kit
Detection of 16 mutations in NRAS codons 12, 13, 59, 61, 117 and 146
NRAS is a member of the RAS family of small GTPases and plays a central role in the MAPK signaling pathways. NRAS has been implicated in the pathogenesis of several cancers.
NRAS mutations are particularly common in melanoma, hepatocellular carcinoma, myeloid leukemias, and thyroid carcinoma. In total, activating mutations in the NRAS genes occur in 13~25% of cutaneous melanomas, 1~6% of colorectal cancer and 1% of lung cancer,
mainly in exons 2, 3 or 4.
The mutation status of NRAS gene is relevant to drug resistance of non-small cell lung cancer treated with tyrosine kinase inhibitors. As a result, NRAS mutations detection supplies evidence for targeted clinical therapy of tumor patients.
Intended Use
AmoyDx® NRAS Mutation Detection Kit is for Research Use Only (RUO).
Technological Principles
The kit uses novel, patented primers and probes to detect mutations in a real-time PCR assay.
The mutant DNA is amplified accurately by the specific primers, and detected by the novel probes.
Highly Specific primers and probes, and a highly validated procedure based on Taq DNA
polymerase contribute to outstanding assay sensitivity and selectivity.
NRAS mutations detected by the NRAS Kit
Exon | Mutation | Base Change | Cosmic ID | Name |
2 | G12D | 35G>A | 564 | NRAS-M3 |
G12S | 34G>A | 563 | NRAS-M10 | |
2 | G13D | 38G>A | 573 | NRAS-M4 |
2 | G13R | 37G>C | 569 | NRAS-M6 |
G12C | 34G>T | 562 | NRAS-M7 | |
G12V | 35G>T | 566 | NRAS-M9 | |
G12A | 35G>C | 565 | NRAS-M11 | |
G13V | 38G>T | 574 | NRAS-M14 | |
3 | A59D | 176C>A | 253327 | NRAS-M15 |
3 | Q61R | 182A>G | 584 | NRAS-M1 |
Q61K | 181C>A | 580 | NRAS-M2 | |
Q61L | 182A>T | 583 | NRAS-M5 | |
Q61H | 183A>C | 586 | NRAS-M8 | |
4 | K117N | 351G>C | \ | NRAS-M16 |
K117N | 351G>T | \ | NRAS-M17 | |
4 | A146T | 436G>A | 27174 | NRAS-M12 |
Key Features and Benefits:
• Simple Procedure — only one step required for sample application, results obtained within 90
minutes.
• High sensitivity and accuracy — can detect 1-5% mutant DNA in a background of wild type
genomic DNA.
• ADx-ARMs technology — employs a patented two-step PCR amplification procedure and
novel fluorescent probe design.
• Easy Standardization — any general PCR lab can perform the test, and technicians obtain
reproducible results without specialized training.
• Reliable product quality — Produced in a dedicated GMP plant, with quality management
systems that have passed Chinese CFDA and international ISO13485 standards.
• Sample type: Fresh, frozen or paraffin embedded tissue